iShares Biotechnology ETF (IBB)
158.44
-0.46 (-0.29%)
USD |
NASDAQ |
Oct 22, 16:00
158.44
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
Customize
| Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.46% | 0.05% | 10.20B | 2.014M |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (All) |
| 0.22% | 34.00% | -168.73M | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks to track the investment results of the ICE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector. The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Mid Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Technology |
| Fund Owner Firm Name | iShares |
| Prospectus Benchmark Index | |
| ICE Biotechnology TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Greg Savage | 13.76 yrs |
| Jennifer Hsui | 9.17 yrs |
| Alan Mason | 5.47 yrs |
| Amy Whitelaw | 3.17 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
86
-168.73M
-4.465B
Category Low
6.183B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of September 30, 2021
Performance Versus Category
As of October 22, 2021. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
Edit comparables
As of October 22, 2021.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Amgen Inc | 8.06% | 209.24 | 0.12% |
| Moderna Inc | 7.84% | 326.54 | -3.84% |
| Gilead Sciences Inc | 6.66% | 67.24 | 0.37% |
| Regeneron Pharmaceuticals Inc | 4.62% | 572.36 | 0.53% |
| Illumina Inc | 3.91% | 409.15 | -0.59% |
| IQVIA Holdings Inc | 3.84% | 256.89 | 0.80% |
| Vertex Pharmaceuticals Inc | 3.83% | 183.52 | -1.91% |
| BioNTech SE ADR | 3.82% | 278.34 | -2.80% |
| Biogen Inc | 3.19% | 264.80 | -2.00% |
| Mettler-Toledo International Inc | 2.60% | 1469.75 | 2.28% |
News
Headline
Wire
Time (ET)
MT Newswires
10/22 13:03
MT Newswires
10/21 12:58
MT Newswires
10/20 12:35
MT Newswires
10/19 12:44
MT Newswires
10/18 12:45
Basic Info
| Investment Strategy | |
| The investment seeks to track the investment results of the ICE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector. The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Mid Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Technology |
| Fund Owner Firm Name | iShares |
| Prospectus Benchmark Index | |
| ICE Biotechnology TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Greg Savage | 13.76 yrs |
| Jennifer Hsui | 9.17 yrs |
| Alan Mason | 5.47 yrs |
| Amy Whitelaw | 3.17 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (10-22-21) | 0.22% |
| 30-Day SEC Yield (3-31-20) | Upgrade |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 24.24 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of October 21, 2021
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 2/5/2001 |
| Last Annual Report Date | 3/31/2021 |
| Last Prospectus Date | 7/30/2021 |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund |
|
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan |
|
| Socially Responsible Fund | No |
News
Headline
Wire
Time (ET)
MT Newswires
10/22 13:03
MT Newswires
10/21 12:58
MT Newswires
10/20 12:35
MT Newswires
10/19 12:44
MT Newswires
10/18 12:45